Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?

When a stock is in a seemingly endless tailspin, it can be tough to take a chance and invest in it. Even if its valuation seems enticing enough to take a position, there's always lingering worry about whether it will only end up falling further. While hitting a 52-week low may sound like shares have become a cheap buy, a new low could still be right around the corner.Iovance Biotherapeutics (NASDAQ: IOVA) has been hitting new lows this year, and it's down more than 75% in the past 12 months. Its performance has been downright abysmal. Although the company does have an approved treatment in its portfolio, there's still no shortage of risk for investors. Is there a reason to expect a turnaround for Iovance, or are you better off simply steering clear of this healthcare stock?Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool